48 withdrawn. 48 Phase 2, 8 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 48 | Withdrawn 48 |
| Phase 1 | 8 | Withdrawn 8 |
| Phase 3 | 3 | Withdrawn 3 |
Follow Gastroenteritis: new trials by email Literature Review of Gastroenteritis trials Research Report on Gastroenteritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis Etrasimod, Placebo, Corticosteroids - Immune Checkpoint Inhibitor-Related Diarrhea and Colitis | Phase 2 | Withdrawn | Yale University | 2026-01-01 | 2026-01-14 | |
| Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis MitoQ, Placebo - Ulcerative Colitis | Phase 2 | Withdrawn | University of Edinburgh | 2025-09-01 | 2026-01-09 | |
| Hydroxocobalamin Approach for Reducing of Calprotectin With Butyrate for Ulcerative Colitis Remission Hydroxocobalamin with Butyrate, Placebo with Butyrate - Ulcerative Colitis | Phase 2 | Withdrawn | Joshua Korzenik | 2024-01-01 | 2024-04-22 | |
| Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's Disease Investigational Product, Placebo - Crohn Disease | Phase 2 | Withdrawn | Telavant, Inc. | 2023-07-30 | 2023-10-19 | |
| Safety and Efficacy Study of TLL018 in the Treatment of Ulcerative Colitis TLL018, Placebo - Ulcerative Colitis | Phase 2 | Withdrawn | TLL Pharmaceutical, LLC | 2022-12-30 | 2022-05-13 | |
| Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients ABX464, Placebo - Crohn Disease | Phase 2 / Phase 3 | Withdrawn | Abivax S.A. | 2022-09-19 | 2024-07-31 | |
| FMT for Remission of Active Ulcerative Colitis in Adults FMT oral, FMT enema, Placebo oral - Ulcerative Colitis, Inflammatory Bowel Diseases | Phase 2 | Withdrawn | University of British Columbia | 2022-03-01 | 2023-05-10 | |
| A Study to Investigate Efficacy and Safety of KBL697 in Patients With Mild to Moderate Active Ulcerative Colitis KBL697, Placebo - Ulcerative Colitis | Phase 2 | Withdrawn | KoBioLabs | 2022-01-14 | 2023-08-02 | |
| Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease BT-11, Active comparator - Crohn's Disease | Phase 2 | Withdrawn | NImmune Biopharma | 2021-11-01 | 2023-06-07 | |
| Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative Colitis Empagliflozin 10 MG, Placebo - Ulcerative Colitis | Phase 2 | Withdrawn | Sadat City University | 2021-10-01 | 2025-07-14 | |
| Pharmacokinetics, Efficacy, Tolerability and Safety of Different Budesonide Oral Gel Doses in Adults' Subjects of Both Genders With Eosinophilic Esophagitis (EoE) Budesonide Gel - Eosinophilic Esophagitis | Phase 2 | Withdrawn | Bazell Pharma AG | 2021-04-23 | 2024-08-23 | |
| Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease GSK2330811, Placebo - Crohns Disease, Crohn's Disease | Phase 2 | Withdrawn | GlaxoSmithKline | 2021-04-05 | 2022-01-14 | |
| A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease JNJ-64304500, Placebo, Adalimumab - Crohn Disease | Phase 2 | Withdrawn | Janssen Research & Development, LLC | 2021-03-03 | 2025-04-27 | |
| Evaluation of Low-Level Laser Therapy Efficacy in Pain Management of Grade 2 Oral Mucositis Induced by Radiotherapy or Chemoradiotherapy: a Study in Patients With Upper Aerodigestive Tract Cancer Basic Oral Care + active LLLT, Basic oral Care + inactive LLLT, Basic Oral Care - Upper Aerodigestive Tract Neoplasms | Phase 2 | Withdrawn | Institut Claudius Regaud | 2021-03-01 | 2021-04-08 | |
| A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis PF-06826647 100 mg QD, PF-06826647 300 mg QD, PF-06826647 600 mg QD - Ulcerative Colitis | Phase 2 | Withdrawn | Pfizer | 2020-09-30 | 2020-12-17 | |
| Efficacy and Safety of LC51-0255 in Subjects With Ulcerative Colitis LC51-0255, Placebo - Ulcerative Colitis | Phase 2 | Withdrawn | LG Chem | 2020-04-01 | 2021-11-15 | |
| Autologous Transplant Targeted Against Crohn's Fludarabine, Cyclophosphamide, Mesna - Crohn's Disease | Phase 2 | Withdrawn | Northwestern University | 2019-11-01 | 2019-11-08 | |
| Vedolizumab Post Op Study Vedolizumab, placebo - Crohn's Disease | Phase 2 | Withdrawn | Marc Schwartz | 2018-12-01 | 2020-05-14 | |
| A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis Itacitinib, Placebo - Moderate to Severe Ulcerative Colitis | Phase 2 | Withdrawn | Incyte Corporation | 2018-09-20 | 2019-12-06 | |
| Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas FE 203799 - Lymphoma, Non-Hodgkin's, Adult, Lymphoma, Hodgkin's, Adult | Phase 1 / Phase 2 | Withdrawn | GlyPharma Therapeutics | 2018-09-01 | 2024-10-24 |
Showing 20 of 48. Sign in to see all of them.
Crohn Disease (19) · Colitis, Ulcerative (15) · Inflammatory Bowel Diseases (8) · Mucositis (7) · Colitis (3) · Hematologic Neoplasms (3) · Eosinophilic Esophagitis (2) · Agnosia (1) · Anemia, Dyserythropoietic, Congenital (1) · Anemia, Iron-Deficiency (1) · Appendicitis (1) · Bacterial Infections (1) · Clostridium Infections (1) · Colonic Diseases (1) · Deglutition Disorders (1)
Digestive System Diseases (47) · Gastrointestinal Diseases (47) · Intestinal Diseases (38) · Inflammatory Bowel Diseases (25) · Colonic Diseases (17) · Colitis (15) · Hemic and Lymphatic Diseases (9) · Hematologic Diseases (8) · Mouth Diseases (7) · Stomatognathic Diseases (7) · Neoplasms (6) · Neoplasms by Site (5) · Immune System Diseases (4) · Infections (3)
Cyclophosphamide (3) · angiotensin I (1-7) (3) · Adalimumab (2) · Adrenal Cortex Hormones (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Mesna (2) · Stem Cell Transplantation (2) · Tacrolimus (2) · vedolizumab (2) · ABX464 (1) · Alemtuzumab (1) · BID protein, human (1) · Blood Component Removal (1) · Butyrates (1)
Tarix Pharmaceuticals (3) · GlaxoSmithKline (2) · Abivax S.A. (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Bazell Pharma AG (1) · Children's Hospital Medical Center, Cincinnati (1) · Children's Oncology Group (1) · Columbia University (1) · GlyPharma Therapeutics (1) · Heidelberg University (1) · Incyte Corporation (1) · Institut Claudius Regaud (1) · Janssen Research & Development, LLC (1) · Johns Hopkins University (1) · Joshua Korzenik (1)
United States (22) · Belgium (2) · United Kingdom (2) · Australia (1) · Canada (1) · Egypt (1) · France (1) · Germany (1) · Netherlands (1) · Norway (1)
Alfred E Slonim, MD (1) · Anurag Singh (1) · Edmund K Waller, MD,PhD,FACP (1) · Elena Kamycheva, MD, PhD (1) · Eran Goldin, MD (1) · Erick J Imbertson, M.D. (1) · Gerald Gollin, MD (1) · Harriet Kluger, MD (1) · Jeffrey A Alexander, MD (1) · Joanne Kurtzberg, MD (1) · Joshua R Korzenik, MD (1) · Kristin Page, MD (1)
PMID 17222320, PMID 21991594, PMID 23188075, PMID 24558033, PMID 40357993, PMID 40603760
2009 (1), 2019 (1), U10CA095861 (1)